视频

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy

 

Authors Rios-Tamayo R, Martín-García A, Alarcón-Payer C, Sánchez-Rodríguez D, Guardia AM, García Collado CG, Jiménez Morales A, Jurado Chacón M, Cabeza Barrera J

Received 27 March 2017

Accepted for publication 28 June 2017

Published 22 August 2017 Volume 2017:11 Pages 2399—2408

DOI https://doi.org/10.2147/DDDT.S115456

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rammohan Devulapally

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Frank Boeckler

Abstract: Multiple myeloma is a very heterogeneous disease with variable survival. Despite recent progress and the widespread use of new agents, patients with relapsed and refractory disease have a poor outcome. Immunomodulatory drugs play a key role in both the front-line and the relapsed/refractory setting. The combination of pomalidomide (POM) and dexamethasone is safe and effective in relapsed and refractory patients, even in those with high-risk cytogenetic features. Furthermore, it can be used in most patients without the need to adjust according to the degree of renal failure. In order to further improve the results, POM-based triplet therapies are currently used. This article highlights the most relevant issues of POM and POM-based combinations in the relapsed/refractory multiple myeloma setting, from a pharmacological and clinical point of view.
Keywords: multiple myeloma, pomalidomide, triplet therapy, dexamethasone

 


摘要视频链接Pomalidomide in multiple myeloma